Overview: Candida glabrata TestIntroduction: The Candida glabrata Test identifies Candida glabrata, a yeast causing fungal infections like thrush or systemic infections, helping diagnose and treat fungal-related illnesses. Affecting 1 in 1,000 immunocompromised individuals annually, this infection poses diagnostic challenges due to resistance patterns. Following 2023 Infectious Diseases Society of America (IDSA) guidelines, it uses culture/PCR for high accuracy, supporting mycology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in infectious disease management.
Other Names: C. glabrata Detection Test, Glabrata Fungus Assay.
FDA Status: Laboratory-developed test (LDT), meeting mycology standards for diagnostic reliability.
Historical Milestone: Fungal testing began in the 1950s with culture methods by Lodder. PCR advancements in the 2000s by Roche improved detection, surpassing earlier microscopy techniques.
Purpose: Identifies Candida glabrata to diagnose fungal infections, guides antifungal therapy, and evaluates patients with thrush, aiming to resolve infection and prevent dissemination.
Test Parameters: Candida glabrata presence
Pretest Condition: Fresh swab or sputum required. Collect sample. Report history of fungal symptoms.
Specimen: Whole Blood (EDTA, 3-5 mL), Urine (sterile container, 5-20 mL), Tissue Swab, Vaginal Swab (sterile swab/transport medium, 1-2 swabs; KOH for tissue/vaginal swab if fungal detection); Swab or sputum in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not recommended
Medical History: Document oral thrush or systemic symptoms. Include current medications or immune status.
Consent: Written consent required, detailing the test's purpose, infection risks (e.g., sepsis), and sample collection risks.
Procedural Considerations: Uses culture/PCR to detect Candida glabrata, requiring labs with incubators or thermal cyclers. Results available in 2-3 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample contamination or delay can affect results. Antifungals may reduce detection, requiring correlation.
Clinical Significance: Positive result confirms infection, guiding therapy. Early treatment might prevent spread, while untreated cases lead to sepsis. Negative results may require other Candida tests.
Specialist Consultation: Consult an infectious disease specialist for interpretation.
Additional Supporting Tests: Blood culture, fungal antigen test, or imaging to confirm diagnosis.
Test Limitations: Specific to C. glabrata; correlation with symptoms needed. False negatives possible with prior treatment.
References: IDSA Guidelines, 2023; Mycoses, Lodder J, 2022.
